S809 A Higher Induction Dosing Regimen of Adalimumab Does Not Enhance Modulation of Downstream Blood Molecular Markers in Patients With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis. (October 2021) - Ferrante, Marc